- About Us
- Nano-Social Network
- Nano Consulting
- My Account
In the final weeks to the start of BioPharm America™, September 9-10, 2008 at the Grand Hyatt Hotel in Atlanta, GA, EBD Group today announced new program highlights covering a wide selection of important industry topics.
The additional program highlights include:
* Rediscovering Anti-Infectives
Big pharma has been reluctant to enter the anti-infectives arena due to pricing pressure, lower profit margins, short therapeutic regimens, manufacturing challenges, and regulatory problems associated with developing drugs for novel microbial targets.
However, the emergence of pandemics, threats of bioterrorism, the role of combination therapies and advances in molecular biology and nanotechnology have ignited big pharma's interest in the anti-infectives space to build up pipelines through licensing agreements and acquisitions.
Dr. William D. Johnston, President, BioBusiness Strategies, Inc. will moderate a panel featuring four leading authorities in anti-infectives, Dr. Edwin W. Ades, Associate Director for Laboratory Science; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention; Mike Bonney, President and CEO, Cubist; Dr. Michael Goldblatt, President and CEO, Functional Genetics; and Dr. Anthony Sedgwick, CEO, Novacta Therapeutics.
This panel will look at the market opportunities in infectious diseases from a research and a business development related perspective, tackling important questions such as: What are the most promising research areas, targets and drugs for infectious diseases? What commercial opportunities are present in vaccines and antibodies? Which business and regulatory models will attract partners and investors?
* New Financing Trends in Drug Development and the Role of Big Pharma and Private Equity
Growing a biopharmaceutical start-up in today's tough financing environment requires the entrepreneur to seek sources of financing beyond the traditional venture capitalist. In addition, the larger biotechnology and pharmaceutical companies are seeking to maximize their view of the biotechnology platforms that might deliver tomorrow's blockbusters.
The major biopharmaceutical companies have established venture capital arms with a dual purpose of 1) significant return on investment and 2) providing insight into emerging technologies and companies that might provide future opportunities for acquisition or partnership. The entrepreneur, in turn, finds value from the depth of knowledge and market validation of a large pharma investor.
Dr. Thomas H. Callaway, General Partner, Georgia Venture Partners will lead a panel of corporate venture capitalists including John Richard, Senior Venture Partner, Nomura Phase 4 Ventures, and Dr. Rajeev Dadoo, Principal, SR One to discuss the emergence of the investment arm of big pharma and how the entrepreneur should approach this potential source of financing.
* The Science and Business of Alzheimer's Disease Therapy
In the last 15 years the major advances in Alzheimer's have resulted from identifying appropriate biomarker endpoints that can track the progression of the disease. However, current cognitive scoring instruments do not accurately track the initiation and progress of the disease until it is too late. There are a number of surrogate biochemical biomarker endpoints that are being developed in addition to innovations in medical imaging that may inform progression and efficacy of new treatment modalities.
Moderated by Dr. Alan Rudolph, Chief Executive Officer, Adlyfe, this session will bring together a panel of scientific and industry leaders from small biotech and large pharma companies with active discovery and development programs to discuss novel advances in the search for effective Alzheimer's disease therapeutics. This panel features Kees Been, Chief Executive Officer, EnVivo Pharmaceuticals; Dr. Xavier Lataste, Head of Neuroscience, Business Development and Licensing, Novartis; Dr. Martin Tolar, Chief Business Officer, CoMentis, and Dr. Shafique Virani, Director Global Business Development, Roche, who will discuss ongoing research and provide an overview of recent deals and business development trends in this area.
EBD Group's events are widely recognized as being the gold standard for highly productive bio-pharma partnering meetings. As for all EBD Group events, partnering at BioPharm America 2008 is powered by partneringONE™, the industry's most advanced partnering system. partneringONE enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with dozens of company targets.
General registration for BioPharm America is now available at
www.ebdgroup.com/bpa/registration.htm. For more information about this global partnering event for the bio-pharma industry, including accommodation and program updates, please go to the event homepage at www.biopharmamerica.com.
Advance media registration for BioPharm America is now available online. Registration is complimentary for credentialed members of the media. To register, please visit www.ebdgroup.com/bpa/press_reg.htm.
About BioPharm America
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. BioPharm America is the only partnering event in North America based on the same winning formula as EBD Group's acclaimed European events BIO-Europe and BIO-Europe Spring®. BioPharm America is simply an unmatched opportunity for companies across the biotech value-chain to meet and do business. For more information please visit www.biopharmamerica.com.
About EBD Group
EBD Group is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business.
EBD Group’s conferences are run in collaboration with leading industry players and international trade associations. They include BIO-Europe, the world’s largest stand-alone life science partnering conference (organized with the support of the Biotechnology Industry Organization, BIO); BIO-Europe Spring®; BioPharm America™ (EBD’s new North American partnering event); and BioEquity Europe (co-organized with BioCentury Publications and BIO).
EBD’s novel, Web-based, partnering service partneringONE™ is also used at numerous third-party events around the world. Outside of the conference format, EBD Group’s consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the USA and Europe.
For more information, please click here
Constantine Theodoropulos, +1-617-292-7319
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016